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immunoprophylaxis: a review
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The recommended dose of Rh immune globulin for postpartum 
Rh immunoprophylaxis is based on an estimation of the volume 
of the fetomaternal hemorrhage, if any, measured as the percent 
of fetal RBCs in a sample of the D– mother’s blood. Laboratory 
methods for distinguishing fetal from maternal RBCs have been 
based on their different blood types (D+ versus D–) or predomi-
nant hemoglobin content (hemoglobin F versus hemoglobin A). 
We conducted a review of the medical literature describing labo-
ratory methods for detecting and quantifying fetal RBCs in ma-
ternal blood samples. We also used data collected for the College 
of American Pathologists Fetal RBC Detection Surveys to deter-
mine which laboratory methods are used currently in hospitals 
in the United States. The rosette screen is used widely for iden-
tifying D– mothers who may require additional doses of Rh im-
mune globulin for postpartum immunoprophylaxis. As the 
rosette screen targets the D antigen, it is not suitable for detecting 
a fetomaternal hemorrhage in D+ mothers or when the D type of 
the fetus or newborn is D– or unknown. The acid-elution (Kleihauer- 
Betke) assay is a sensitive laboratory method for quantifying 
a fetomaternal hemorrhage, but it is tedious, often inaccurate, 
and difficult to reproduce. Flow cytometry, using anti-D or anti- 
hemoglobin F reagents, offers a more precise quantification of fe-
tal RBCs in maternal blood. However, flow cytometry services for 
this function are available in relatively few hospital laboratories 
in the United States because of logistic and fiscal impediments. 
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In the United States, standard practice for determining the postpartum dose of Rh immune globulin (RhIG) be-gins with a laboratory measurement of the percent of 
fetal RBCs in a sample of maternal blood followed by a cal-
culation of the estimated volume of the fetomaternal hem-
orrhage (FMH) (mL of RBCs).1–6 Most hospital laboratories 
perform an initial qualitative assay for fetal RBCs in the 
mother’s blood using the rosette screen for D+ fetal RBCs.7 
If the rosette screen is positive, most laboratories perform a 
quantitative measurement of the percent of fetal RBCs in a 
sample of the mother’s blood using the Kleihauer-Betke (K-
B) acid-elution assay.7 Evaluations of the various versions 
of the K-B acid-elution assay consistently conclude that the 
assay is imprecise and lacks reproducibility for quantifying 
fetal RBCs in maternal blood.5,8,9 Flow cytometry (FC) offers 
a more precise and reproducible methodology for quantify-
ing fetal RBCs in a sample of maternal blood, but logistical 
and fiscal factors have impeded widespread implementa-
tion of FC assays for this purpose in hospitals in the United 
States.4,10 Recognizing the technical limitations of the se-
quential rosette screen and K-B acid-elution assay, the edi-
tors of the AABB Technical Manual recommend routinely 
adding one additional vial of RhIG to the number calculat-
ed using the standard formula for determining the postpar-
tum dose of RhIG (one vial of 300 µg of anti-D per 15 mL 
of RBC FMH).5 Ramsey, writing for the College of Ameri-
can Pathologists (CAP) Transfusion Medicine Resource 
Committee, analyzed the results submitted by nearly 1600 
laboratories that participated in the CAP Proficiency Test-
ing survey for Fetal RBC Detection to determine the meth-
ods used to calculate the dose of RhIG.3 He reported that in 
three of the four calculation exercises in this survey, 20 to 
30 percent of participating laboratories underestimated the 
necessary dose of RhIG.3 Ramsey concluded that laborato-
ries performing quantification of FMHs should review their 
procedures and training for calculating RhIG dosage.3
 The following review supplements Ramsey’s analysis of 
methods for calculating the dose of RhIG and provides an 
updated review of laboratory methods for quantifying the 
number of fetal RBCs in a sample of maternal blood. For this 
review, we focused on those laboratory methods reported 
by 1911 laboratories participating in the CAP’s 2009 HBF-
01 Fetal RBC Detection Survey.7 We confirmed the avail-
ability of commercially marketed test kits that have been 
cleared by the US Food and Drug Administration (FDA) for 
clinical use in the United States by a search of Internet Web 
sites. There is no standard format for comparing the per-
formance of different laboratory assays for detecting and 
quantifying fetal RBCs. For any given volume of an FMH, 
the percent of fetal RBCs in a sample of maternal blood will 
vary in proportion to the mother’s RBC volume. For pur-
poses of this review, we selected the detection of 0.6 per-
cent fetal RBCs in a sample of maternal blood to represent 
an assay’s ability to detect a 30-mL FMH, as proposed by 
Bayliss and colleagues8 and by Sebring and Polesky.9 This 
degree of sensitivity is critical, because standard practice in 
the United States is to calculate the dose of RhIG based on 
the premise that one 300-µg vial of RhIG will suppress D al-
loimmunization by an FMH of 30 mL (or 15 mL of RBCs).1–6 
Failure to detect a 30-mL FMH could result in inadequate 
dosing of RhIG.3
Laboratory Methods of Historical Interest
Microscopic Weak D Test
 If a microscopic weak D test (formerly known as the Du 
test) is performed on a sample of blood from a D– mother after 
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being performed in other laboratories for similar reasons” 
(personal communication, Paul Ness, August 2010).
Qualitative Screens for Fetal RBCs in Maternal 
Blood
Rosette Screen for D+ RBCs
 In 1982, Sebring and Polesky9 described a modified mi-
croscopic weak D test in which ficin-treated indicator RBCs 
enhanced the detection of D+ fetal RBCs by forming aggre-
gates (rosettes). Sebring and Polesky’s rosette screen was 
adapted from a generic model described by Helderweirt and 
Sokal,24 who used “incomplete antibodies” to blood group 
antigens to identify minor populations of RBCs admixed in 
major populations. In Sebring and Polesky’s rosette screen, 
a sample of maternal D– RBCs was examined microscopi-
cally after adding reagent anti-D and ficin-treated R2R2 
indicator RBCs. If D+ RBCs were present, the D+ ficin-treat-
ed indicator RBCs formed aggregates (rosettes) around the 
anti-D–coated fetal RBCs (Fig. 1). Sebring and Polesky9 
reported that 100 percent of 20 technologists participating 
in a study of the rosette screen identified a 0.6 percent ad-
mixture of D+ cord RBCs in D+ adult RBCs, corresponding 
to a 30-mL FMH. In contrast, only 17 of 20 (85%) technolo-
gists detected the 0.6 percent admixture using the micro-
scopic weak D test.9 Sebring and Polesky25 subsequently 
published a letter to the editor of Transfusion alerting readers 
a large FMH (>30 mL), the presence of D+ fetal RBCs may 
be inferred by observing mixed-field agglutination.10 Based 
on this observation, the microscopic weak D test was used 
historically by many laboratories as a screen for an FMH. 
As recently as 1980, the majority of laboratories participat-
ing in CAP’s Immunohematology Survey reported using the 
microscopic weak D test as a screen for an FMH.11 Using 
this test as a screen, 12.2 percent of nearly 2000 laborato-
ries obtained a false-negative result on a proficiency sample 
that contained approximately 0.6 percent D+ RBCs.11 In an 
evaluation by Riley and colleagues,12 the microscopic weak 
D test failed to detect 25 percent of simulated FMHs pre-
pared as admixtures of 0.5 percent D+ cord RBCs in D– 
adult RBCs. In an evaluation by Sebring,13 the microscopic 
weak D test did not reliably detect a simulated 30-mL FMH 
in an admixture of D+ and D– RBCs. Nance and Garratty14 
and Wenz and Apuzzo15 attempted to improve the sensi-
tivity by adding polyethylene glycol (PEG) to the serologic 
reactants. In a direct comparison, Bayliss and colleagues8 
found that the addition of PEG did not offer a significant 
advantage over the conventional microscopic weak D test.
 More-sensitive laboratory assays are currently avail-
able to screen for an FMH. The microscopic weak D test is 
no longer recommended as a screen for an FMH.16–18
Enzyme-Linked Antiglobulin Test (ELAT)
 In 1982, Ness19 and Riley and colleagues12 described an 
enzyme-linked antiglobulin test (ELAT) that targeted D+ 
RBCs and was reported to be capable of detecting a simu-
lated 12.5-mL FMH, based on testing for D+ cord RBCs ad-
mixed with D– RBCs. Ness and colleagues20 also reported 
the results of using their ELAT to quantify FMHs in 789 
consecutive D– postpartum mothers who had delivered D+ 
newborns. There were 117 (14.8%) samples from mothers 
who had a detectable FMH, including 8 (1%) who had an 
FMH greater than 30 mL and required more than one vial 
of RhIG. They reviewed each case for high-risk features 
that might predict an FMH and concluded that there were 
neither maternal nor newborn characteristics that reliably 
predicted an FMH. Greenwalt and colleagues21 developed a 
modified ELAT for quantifying D+ RBCs in the circulations 
of D– mothers. By stabilizing RBCs using 0.05 percent glu-
taraldehyde, they decreased in vitro hemolysis, which had 
been troublesome in other assays.22,23 They reported that 
their ELAT was capable of detecting as small a volume as 
2 mL of D+ cord RBCs admixed in 1600 mL of D– adult 
RBCs.21
 In a personal communication, Dr. Paul Ness informed 
the authors of this review that “. . . although the ELAT for 
FMH provided accurate clinical information that enabled 
the laboratory to both screen for FMH and quantify the 
unusually large FMH that was detected, standardized tests 
were not developed and licensed by the FDA. In the absence 
of a standardized licensed test, we discontinued the routine 
use of the test in our laboratory and believe that it is not 
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Fig. 1. The rosette screen. One drop of the manufacturer’s reagent-
reduced, alkylated, and buffered IgG anti-D in bovine albumin (Fetal 
Bleed Screening Test, Immucor/Gamma) was added to one drop 
of a 3% suspension of Immucor’s positive control RBCs (0.6% 
group O D+ RBCs in 99.4% of group O D– RBCs) and incubated 
at 37ºC for 15 minutes. After washing the RBCs four times and 
decanting the supernatant, one drop of indicator RBCs (0.5% sus-
pension of ficin-treated group O R2R2 RBCs) was added. The con-
tents were mixed gently and the tube centrifuged to form an RBC 
button. The RBCs were resuspended and examined for aggregates 
(rosettes) microscopically at low power (100×). The presence of 
aggregates of RBCs in the low-power field represents a positive 
result, interpreted to indicate that D+ fetal RBCs are present in the 
maternal blood.
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that the rosette screen was not sufficiently sensitive to de-
tect a 30-mL FMH if the Rh phenotype of the cord RBCs 
was a weak D. The rosette screen was quickly recognized to 
be more accurate and reliable than the microscopic weak D 
test for detecting a significant FMH in a D– mother.26 Com-
mercially marketed kits are available in the United States 
(Fetal Bleed Screening Test; Immucor/Gamma, Norcross, 
GA). Another widely used kit (Fetalscreen; Ortho-Clinical 
Diagnostics, Raritan, NJ) was recalled from the market in 
January 2005 and is no longer available. In April 2009, 
the FDA cleared FetalScreen II/Fetal Maternal Hemor-
rhage Screening Test (Alba Bioscience, Edinburgh, UK). 
FetalScreen II kits are currently marketed in the United 
States by Ortho-Clinical Diagnostics, Raritan, New Jersey. 
The rosette screen will detect an FMH as small as 10 mL 
of D+ whole blood.4,5 Of 1911 participants in the CAP 2009 
HBF-01 Fetal RBC Detection Survey who reported results 
for qualitative screening for FMH, 1907 (99.8%) used the 
Fetal Bleed Screening Test (Immucor/Gamma) kit.7
 A positive rosette screen result provides (only) qualita-
tive evidence of a large-volume FMH that may require addi-
tional doses of RhIG. Retesting the mother’s blood sample 
using a quantitative method is necessary to determine the 
percentage of D+ fetal RBCs in the maternal blood sample, 
which is the basis for estimating the volume of the FMH. 
Because the targeted analyte is the blood group antigen D, 
not hemoglobin F (HbF), the rosette screen is not a suitable 
assay for detecting FMHs in all women. Using a standard 
table of blood group genotype frequencies,27 we calculated 
that approximately 40 percent of pregnant Caucasian D– 
mothers will be carrying a D– fetus. Therefore, by its de-
sign—targeting D+ RBCs in D– mothers’ blood—the rosette 
screen will not detect approximately 40 percent of signifi-
cant FMHs in D– mothers, if the rosette screen is (mis)ap-
plied to screen for an FMH in a D– mother. Also, the rosette 
screen cannot be used in D+ mothers to test for an FMH, 
because maternal D+ RBCs will be agglutinated.
Gel Agglutination Cards
 Salama and colleagues28 and David and colleagues29 
adapted a brand of gel agglutination cards (DiaMed, Cress-
ier sur Morat, Switzerland), which are marketed in Europe 
but not in the United States, to detect D+ fetal RBCs in D– 
maternal blood samples. They evaluated the card assay’s 
performance by adding monoclonal IgG anti-D to admix-
tures of D+ and D– RBCs (0.05–0.5% D+ RBCs) and test-
ing for agglutination using DiaMed anti-IgG gel cards. The 
results were compared with those for detecting fetal RBCs 
by a standard acid-elution staining method for HbF. The 
authors reported that their gel agglutination card assay had 
comparable sensitivity with the acid-elution staining assay 
and detected all admixtures of D+ RBCs that were greater 
than 0.2 percent.28,29 Ben-Haroush and colleagues30 ana-
lyzed blood samples from 118 D– postpartum women for 
fetal RBCs by both gel agglutination and flow cytometry 
(anti-HbF), and reported that the gel agglutination test 
failed to detect FMHs reliably in the range of 0.1 to 10.0 
mL. Subsequently, Agaylan and colleagues31 described a 
particle gel immunoassay using superparamagnetic par-
ticles coated with monoclonal anti-D. The antibody-coated 
particles were isolated by a magnetic particle concentrator 
and placed in the reaction chamber of a DiaMed gel card for 
centrifugation and reading. They reported that this version 
of the gel agglutination card assay was capable of detecting 
as few as 0.3 percent of D+ RBCs admixed in D– RBCs.31
 Although a version of the gel agglutination card as-
say is marketed as a screen for FMH (ID-FMH Screening 
Test, DiaMed), there are few data evaluating its use for this 
function. None of the 1911 laboratories submitting results 
in CAP’s 2009 HBF-01 Fetal RBC Detection Survey Partici-
pant Report indicated using a gel agglutination card assay 
to screen for FMH.7 However, CAP participants are primar-
ily located in the United States, and, therefore, statistics 
from this survey do not reflect use elsewhere. Both versions 
of the gel agglutination assay use a commercially marketed 
gel card, offering the option of a simple, convenient, and 
standardized alternative to the rosette method for screen-
ing for an FMH. However, these gel agglutination cards are 
not commercially marketed or cleared by the FDA for clini-
cal use in the United States. Further comparative testing is 
required before their role as an initial screen for FMHs can 
be determined.
Quantitative Methods for Measuring Fetal RBCs in 
Maternal Blood Samples 
K-B Acid-Elution Assay
 In 1957, Kleihauer, Braun, and Betke32 described an 
acid-elution and staining assay for quantifying small pop-
ulations of fetal RBCs in postpartum samples of maternal 
blood. Their assay was based on a prior observation by Kor- 
ber,33 who reported that HbF was more resistant to alkali 
denaturation than HbA. Kleihauer, Braun, and Betke32 
applied Korber’s observation to distinguish fetal HbF- 
containing RBCs on maternal peripheral blood smears 
after a temperature-controlled elution of HbA using citric 
acid. HbF was not eluted from fetal RBCs, which stained 
dark red by hematoxylin and eosin. In contrast, citric acid 
readily eluted HbA from adult RBCs, which stained mini-
mally (pink “ghosts”) by hematoxylin and eosin. Kleihauer, 
Braun, and Betke’s original 1957 publication is the one cited 
by most investigators and reviewers when referencing the 
origin of the K-B acid-elution assay. However, this article in 
the German language consists of only a brief two-paragraph 
note containing black-and-white photographs of stained 
blood smears, a minimal description of the technical pro-
cedure, and no data of results.32 In 1958, Betke and Klei-
hauer34 published a detailed technical report, and in 1960, 
Kleihauer and Betke35 updated the technical procedure of 
the original KBB assay, which is now popularly known as 
the K-B acid-elution assay.36 In brief, the K-B acid-elution 
assay for differential staining of adult and fetal RBCs is per-
formed by fixing thin peripheral blood smears in 80 percent 
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ethanol, immersing the slides in citric acid–sodium phos-
phate buffer (which elutes all hemoglobins except HbF), 
and staining the dried smears using hematoxylin and eo-
sin (Fig. 2). The percentage of darkly stained fetal RBCs 
among the lightly stained adult RBCs is determined by mi-
croscopic examination. In 1962, Shepard and colleagues37 
applied the K-B acid-elution assay to study the distribution 
of HbF in fetal RBCs, as well as in RBCs from adults with 
sickle cell anemia, thalassemia, aplastic anemia, and he-
reditary persistence of HbF. The descriptions by Shepard 
and colleagues37 are among the earliest of “F cells” (adult 
RBCs containing HbF), although the term “F cell” was not 
introduced until 13 years later by Boyer and colleagues.38 
Shepard and colleagues also confirmed prior observations 
that the proportion of HbA and HbF in newborns’ RBCs 
varies widely and that the percentage of HbF in newborns’ 
RBCs correlates better with the gestational age than with 
birth weight.39,40 Clayton and colleagues41–44 evaluated the 
optimal technical conditions for performing the K-B acid-
elution assay. They observed that the citric acid–phosphate 
buffer must be prepared at precisely pH 3.2 for optimal elu-
tion, which was performed after adding methylene blue to 
the citric acid–phosphate buffer at 50ºC and cooling it to 
37ºC for a 15-minute elution. Using this modification, Clay-
ton et al.41 reported accurate detection of cord RBCs in dilu-
tions as high as 1:100,000 in adult RBCs, which calculates 
to an FMH of approximately 0.5 mL or one drop of fetal 
blood in the entire maternal circulation.
Modified K-B Acid-Elution Assay: Commercially 
Marketed Reagents and Kits
 Commercially marketed kits of reagents are available 
in the United States for performing the K-B acid-elution 
assay using the original 37ºC elution (Fetal-Hemoglobin–
Differential Stain Kit Modified Kleihauer Technique, Eng 
Scientific, Inc., Clifton, NJ; Fetal Hemoglobin Kit, Sigma-
Aldrich, St. Louis, MO). Also, kits are available that substi-
tute the original 37ºC elution for a more convenient room 
temperature elution (Fetal Cell Stain Kit, Simmler, Inc., 
High Ridge, MO; Fetal Hemoglobin–Differential Staining 
Kit/Room Temperature Procedure, Eng Scientific, Inc.: Fe-
tal Hemoglobin/For the Identification of Fetal Erythrocytes 
in the Presence of Adult Red Cells, Sure-Tech Diagnostic 
Associates, St. Louis, MO). Of 1010 laboratories which par-
ticipated in CAP’s 2009 HBF-01 Fetal RBC Detection Sur-
vey and reported results for the K-B acid-elution assay, 976 
(96.6%) used one of these commercially marketed kits, and 
34 (3.4%) reported using an in-house acid-elution assay.7
Modified K-B Acid-Elution Assay: Automated 
Detection
 A significant limitation of the K-B acid-elution assay is 
the imprecision of only one observer’s subjective interpreta-
tion of the different shades of color of stained RBCs, as well 
as the relatively small number of RBCs that can be counted 
manually by even the most dedicated technologist. The con-
sequence is a wide variation in results reported by differ-
ent observers of the same blood smears.5 To address this 
issue, Cupp and colleagues,45 Medearis and colleagues,46 
Ravkin and Temov,47 and Pelikan and colleagues48,49 pro-
posed automated laboratory systems designed to increase 
the number of RBCs scanned and improve the objectiv-
ity of end point determinations. The Pelikan automated 
computer-assisted microscopy system consisted of an au-
tomated scanning stage, microsetting motor controls, and 
bright-field analysis using green and red absorption filters. 
The system counted the percentage of fetal RBCs in 1517 
low-power fields (10× microscope objective) with superior 
precision compared with the results reported by investi-
gators scanning 400 high-power fields (40× microscope 
objective). Pelikan and colleagues48 compared results for 
admixtures of fetal and adult RBCs and reported superior 
determination of fetal RBCs in the range from 0.0001 to 
0.001 percent compared with the standard manual K-B acid-
elution method, but comparable results in the range of 0.01 
to 1.0 percent.
Fig. 2. The Kleihauer-Betke acid-elution assay. The peripheral 
blood smear was prepared to simulate an FMH by mixing two drops 
of EDTA-anticoagulated positive control adult whole blood (pre-
pared by mixing 1 part cord blood and 50 parts normal adult blood) 
and three drops of 0.85% sodium chloride. The estimated cord 
RBC to adult RBC ratio was 3.6 percent. After air-drying, the slide 
was placed in 80% reagent alcohol (Simmler, Inc.) for 5 minutes 
at room temperature. After rinsing in distilled water, the slide was 
placed in 0.081 M citrate buffer (Fetal Cell Buffer, Simmler, Inc.) 
for 10 minutes at room temperature. The slide was immediately 
placed in Erythrocin-B, fast green (Fetal Cell Stain, Simmler, Inc.) 
for 3 minutes. The slide was rinsed thoroughly in distilled water and 
examined under a microscope (200×). Fetal RBCs stained dark 
reddish-pink in contrast to adult RBCs, which appear light pink 
(“ghosts”).
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Modified K-B Acid-Elution Assay: Standardizing 
Enumeration
 Several modifications of the K-B acid-elution assay 
have been proposed to standardize or otherwise improve 
counting the relatively few darkly stained fetal RBCs among 
the relatively large number of lightly stained adult RBCs. 
Woodrow and Finn50 proposed standardizing the number 
of fetal RBCs counted by designating a specified number 
of low-power fields to be examined. Finn and colleagues51 
standardized the number of differentially stained RBCs 
counted on the blood smear in a defined time, and Jones52 
proposed standardizing the volume (2 mL) for preparing 
the blood smear using a mechanical spreader. Howarth and 
colleagues53 reported that performing acid elution on only 
half of the blood smear improved the count of RBCs on the 
blood smear.
Alternative Elution Assay (Elute HbF, not HbA)
 Kabat54 described an alternative elution and staining 
method based on Itano’s prior observation that HbA is less 
soluble in concentrated salt solutions compared with HbF.55 
After a peripheral blood smear has been eluted in concen-
trated potassium phosphate buffer, adult RBCs containing 
HbA stain bright red, whereas fetal RBCs appear as clear 
ghosts (i.e., the reverse of the K-B acid-elution assay). Ka-
bat54 used this elution assay to study the concentrations of 
HbA and HbF in fetal RBCs during the switch in synthesis 
of hemoglobins in human development. We are not aware 
that this assay has been applied in clinical laboratories for 
the detection of fetal RBCs in maternal blood.
Modified K-B Acid-Elution Assay: Limitations
 Nearly all investigators evaluating the various versions 
of K-B acid-elution assays report a wide range of inter- 
observer variation, as well as poor reproducibility of re-
sults.5,8,9 Also, although most infants cease to produce high 
levels of HbF by 6 months of age, healthy-appearing adults, 
as well as adults with certain inherited hemoglobinopathies 
or acquired diseases of hematopoiesis, produce RBCs con-
taining varying percentages of HbA and HbA2 and a small 
subset of RBCs containing HbF (F cells).3,56–59 The percent 
age of F cells in adults is genetically determined, and consid-
erable variation has been observed.58 In most adults, HbF 
represents less than 0.6 percent of the total Hb.57 Most nor-
mal adults (85%) have 0.3 to 4.4 percent F cells.57 Women 
have higher percentages of F cells than age-matched men, 
raising the possibility that there is an X-linked factor in the 
control of Hb synthesis.59 Probably, the most problematic 
F cells for purposes of calculating the dose of RhIG after a 
D– mother delivers a D+ newborn are those F cells that in-
crease during pregnancy.60–66 In approximately 25 percent 
of pregnant women, HbF starts to increase after 8 weeks’ 
gestation and may reach 7 percent by 32 weeks.65,66
Flow Cytometry
Anti-D Method
 In an effort to move beyond the limitations of the rosette 
screen and K-B acid-elution assays, investigators have pro-
posed several applications of FC technology as an alterna-
tive to quantifying fetal RBCs in maternal blood. Initial FC 
assays targeted the D antigen on fetal RBCs, distinguishing 
D+ fetal RBCs from D– maternal RBCs using polyclonal or 
monoclonal anti-D reagents.46,67–74 Nance and colleagues67 
compared the results of testing mixtures of D+ cord RBCs 
and D– adult RBCs by the rosette screen, K-B  acid elution 
assay, and an FC (anti-D) assay. They reported that results 
by FC (anti-D) were more accurate, reproducible, and sen-
sitive.67 They also tested postpartum blood samples from 56 
D– women by the K-B acid-elution assay and FC (anti-D) 
assay. They observed that when significant FMHs did occur 
(greater than or equal to 0.6% of fetal RBCs), FC (anti-D) 
results were consistently lower than those measured by the 
K-B acid-elution assay. Well-controlled FC (anti-D) assays 
are capable of detecting 0.1 percent of D+ RBCs admixed in 
D– RBCs.4 An FC (anti-D) reagent (Quant-Rho FITC anti-
D, Alba Bioscience Limited, Edinburgh, UK) has been FDA 
cleared [510 (k)] for clinical use in the United States (Quo-
tient Biodiagnostics, Newtown, PA). Figures 3A and 3B il-
lustrate how monoclonal anti-D reagents can be applied to 
detect FMHs by FC. Figure 3A is a histogram illustrating 
the result of testing a blood sample prepared to simulate an 
FMH by mixing 1.5 percent of cord RBCs in adult RBCs and 
testing using Quanta-Rho FITC. Figure 3B is a histogram 
illustrating the result of testing the same mixture of cord 
and adult RBCs and testing using Chemicon’s monoclonal 
anti-D (Millipore, Billerica, MA).
Fig. 3. (A) Histogram 
illustrating application of 
FC to quantify simulated 
FMHs using a mixture of 
1.5% D+ cord RBCs in 
D– adult RBCs (Fetal-
trol, Trillium Diagnostics) 
stained using monoclonal 
anti-D (Quant-Rho FITC). 
Adult RBCs (left) are 
separated from cord RBCs 
(right). (B) Illustrates the 
same mixture of 1.5 D+ 
cord RBCs in D– RBCs 
stained with monoclonal 
anti-D (Chemicon anti-D, 
Millipore, Billerica, MA).
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Anti-HbF Method
 FC assays that target D+ fetal RBCs are a logical and 
sensitive strategy for identifying D– postpartum moth-
ers who may require additional doses of RhIG. However, 
assays that target the D antigen cannot be applied to de-
tection of FMHs in D+ mothers or in cases in which the D 
type of the fetus is D– or not known. For these reasons, FC 
assays have been developed that target fetal HbF, thereby 
combining the broader clinical applicability of a test for 
HbF-containing RBCs with the increased sensitivity of an 
FC assay.75–85 Davis and colleagues75 developed a rapid FC 
assay for routine clinical use for detecting FMHs using a 
fluorescein isocyanate-conjugated hybridoma anti-HbF. 
The authors were able to process five maternal blood sam-
ples and controls in less than 1 hour using this method. The 
assay had good correlation with the K-B acid-elution assay 
(r2 = 0.86) and superior precision with a CV of less than 
15 percent for blood samples with greater than 0.1 percent 
fetal RBCs. Their analysis of 150 blood samples from non-
pregnant adults, including persons with increased F cells 
as a result of hemoglobinopathies and hereditary persis-
tence of HbF, gave a mean value of 0.02 percent of fetal 
RBCs. Autofluorescent leukocytes, often a problem with 
other FC methods, were excluded by gating. Davis and col-
leagues75 evaluated their assay using mixtures of cord and adult 
RBCs and concluded that their FC (anti-HbF) assay was prac-
tical, more precise, and technically superior to the K-B acid- 
elution assay. This method required several washing steps, 
but was subsequently modified to eliminate the time- 
consuming washes.80 Reagents for this assay are marketed 
in Europe (QuikQuant, Trillium Diagnostics, Brewster, ME), 
but not in the United States. Radel and colleagues86 devel-
oped an FC (anti-HbF) method that also included an FC 
determination of the D type of RBCs using a monoclonal 
anti-D. This combination method for detecting HbF- 
containing RBCs and determining the D type expands on 
the fixation-permeation FC (anti-HbF) method and FC 
quantification of an FMH in a single assay. Chen and col-
leagues87 described an FC (anti-HbF) reference method to 
quantify F cells in pertinent disease states. Although this 
method is intended to quantify adult F cells, not fetal RBCs, 
its technical precision may offer an improved approach to 
distinguishing fetal RBCs from F cells in postpartum wom-
en whose dosing for RhIG is complicated by disease-related 
increased F cells. The authors are aware of only one FDA-
cleared, commercially marketed FC (anti-HbF) reagent kit 
(Fetal Hemoglobin Kit, Caltag Laboratories, Burlingame, 
CA) (Fig. 4).
 There is no consensus among proponents of FC 
assays concerning the relative advantages and disadvan-
tages of using anti-D versus anti-HbF reagents for quanti-
fying an FMH in a D– mother. Regarding ease of use, the 
availability of fluorochrome-conjugated anti-D reagents 
overcomes the time-consuming aspects of early two-step 
methods for reacting RBCs with polyclonal anti-D, 
followed by fluorochrome-conjugated anti-IgG.88 On the 
other hand, anti-HbF reagents require RBCs to be fixed 
and permeabilized to permit interaction with intracellular 
HbF before staining, a more time-consuming process than 
reacting anti-D reagents with D on the surface of the RBC 
membrane. All reports of FC (anti-D) and FC (anti-HbF) 
methods that we identified using PubMed and reviewed 
for this article claim improved sensitivity compared with 
the K-B acid-elution method. However, we were not able 
to identify a study that directly compared the sensitivities 
of the FC (anti-D), FC (anti-HbF), and K-B acid-elution 
assays. Davis and colleagues75 reported that their FC (anti-
HbF) method had a satisfactory linear correlation with the 
Fig. 4. (A) Histogram illustrating the application of FC to quantify a simulated FMH using monoclonal anti-HbF (Fetal Hemoglobin Kit, Caltag 
Laboratories) and adult RBCs (negative control without admixture of adult RBCs with cord RBCs; Fetalrol, Trillium Diagnostics). Adult RBCs 
(left) are detected, as is the normal content of adult F cells (miDle region), but no cord RBCs are visualized (right region). (B) This sample 
was prepared to simulate the minimally detectable FMH (0.21% cord RBCs), in which fetal RBCs (right region) are readily distinguished from 
adult F cells (miDle region). (C) This sample was prepared to simulate a significant FMH (1.50% cord RBCs).
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K-B acid-elution assay in the range of 0 to 1.6 percent. They 
noted that, as with the K-B acid-elution assay, a greater 
number of F cells can contribute to an apparent increase 
in the number of fetal RBCs using their FC (anti-HbF) as-
say, although still yielding values of less than 0.1 percent fe-
tal RBCs and not contributing to a clinically significant level 
of false-positive results. Thus, a major advantage of the FC 
(anti-HbF) method—provided it is adequately controlled—
is that F cells can be distinguished and omitted in the final 
fetal RBC frequency measurement.88 An FDA-cleared con-
trol product is available in the United States (Fetaltrol, Tril-
lium Diagnostics) for documenting and monitoring the per-
formance of test methods used to determine fetal RBCs in 
maternal blood samples. This product consists of three as-
sayed mixtures of D– adult RBCs and D+ cord RBCs in the 
ranges of 0 to 0.02  percent (negative), 0.1 to 0.3  percent 
(low positive), and 0.79 to 1.60  percent (high positive) cord 
RBCs. Kennedy and colleagues89 conducted a retrospective 
audit of test results on blood samples from 14 women with 
suspected FMHs. The samples had been tested routinely by 
K-B acid-elution assay, as well as by FC using conjugated 
FITC anti-D monoclonal Ig and by directly conjugated PE 
anti-HbF. They observed that the K-B acid-elution assay 
potentially overestimated FMHs in comparison to FC, and 
that FC (anti-HbF) labeling potentially underestimated the 
volume of massive FMHs compared with FC (anti-D). They 
followed up with a study of simulated FMHs consisting of 
mixtures of D+ cord RBCs in adult D– RBCs. In this study, 
FC (anti-HbF) underestimated the percentage of cord RBCs 
compared with FC (anti-D), but only in the subset of sam-
ples containing at least 1 percent cord RBCs.89 There was 
no significant difference in results for samples containing 
0.06 percent or less fetal RBCs. Dziegiel and colleagues90 
had a fortuitous opportunity to address the concern raised 
by Kennedy and colleagues,89 i.e., that the FC (anti-HbF) 
method underestimates large FMHs, when they applied 
their FC (anti-HbF) assay to blood samples from a postpar-
tum woman with an estimated 314-mL FMH. In that study, 
Dziegiel and colleagues found close agreement of their 
measurement of fetal RBCs using FC (anti-HbF) and using 
FC with anti-Fya, anti-s, and anti-Jkb to separate fetal and 
maternal RBC populations. They concluded that there was 
no systematic deviation of measurements by FC (anti-HbF) 
compared with their reference blood group method.91
Discussion
 According to the Participant Summary for CAP’s 2009 
HBF-01 Fetal RBC Detection, only 44 of 1054 (4.2%) partici-
pating laboratories reporting results for quantifying fetal RBCs 
used FC and 1010 (95.8%) used the K-B acid-elution assay.7 All 
44 laboratories reporting FC results used anti-HbF reagents.7 
Most participant laboratories (99.8%) used the commercially 
marketed rosette screen (Fetal Bleed Screening Test, Immu-
cor/Gamma) as their initial qualitative screen. Most laborato-
ries using the K-B acid-elution assay (96.6%) reported using 
one of the commercially marketed kits.7
 Despite multiple evaluations reporting false-positive 
results associated with the rosette screen, this assay remains 
the most widely used in the United States for initial screen-
ing for an FMH. The rosette screen is sensitive, convenient, 
and relatively quick, taking approximately 15 minutes to 
prepare and interpret a maternal blood sample. Blood bank 
technologists are accustomed to evaluating the end point of 
microscopic mixed-field agglutination. There are multiple 
options for selecting an FDA-cleared commercially mar-
keted kit for reagent kits for quantifying fetal RBCs using 
modified K-B acid-elution assays. The conclusions of all 
published evaluations that we reviewed, as well as the opin-
ions of our laboratory’s technologists who perform the K-B 
acid-elution assay, are that the assay has significant tech-
nical limitations. Nevertheless, the K-B acid-elution assay 
remains the standard quantitative assay of fetal RBCs in the 
United States.
 Despite the evidence that FC can offer improved accu-
racy and reproducibility of results for quantifying FMHs, 
few hospitals in the United States use FC assays for routine 
management of postpartum Rh immunoprophylaxis. The 
primary reason in our own hospital and, we believe, in most 
others is the requirement for availability of FC services 
around the clock to ensure that all postpartum D– moth-
ers receive a laboratory-based determination for the dose 
of RhIG before they are discharged from the hospital. Al-
though clinical, accreditation, and regulatory requirements 
allow hospitals to administer RhIG as late as 72 hours af-
ter delivery, many patients are discharged on short notice 
and well before 72 hours after delivery. Even if a hospital 
has FC services for other clinical applications, few hos-
pitals have technically proficient personnel support for 
round-the-clock FC services. In contrast, the relatively low- 
technology requirements for quantifying fetal RBCs by the 
K-B acid-elution assay generate a numerical result (albeit 
questionably accurate). Thus, the K-B acid-elution assay 
has remained the standard of practice for quantifying FMHs 
in the United States for more than five decades. To accom-
modate the recognized imprecision of the K-B acid-elution 
assay, a standard of practice has evolved to routinely add 
one additional vial of RhIG to the calculated dose.3–5 This 
formula for calculating the dose of RhIG—including the ad-
dition of the compensatory extra vial—is incorporated in 
the RhIG Dose Calculator, which is recommended by CAP’s 
Transfusion Medicine Resources Committee and posted on 
the CAP Web site (www.cap.org: CAP Home / Committees 
and Leadership / Transfusion Medicine Resource Com-
mittee / Transfusion Medicine Topic Center / RhIG Dose 
Calculator; accessed August 18, 2010). D– women with 
diseases known to be associated with an increased percent-
age of F cells (sickle cell anemia, thalassemia, hereditary 
persistence of HbF, and certain other diseases of hemato-
poiesis) require special management for postpartum Rh 
immunoprophylaxis. The detection of D+ fetal RBCs by the 
rosette screen is not compromised by the presence of an 
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increased number of maternal D– F cells. However, many 
technologists have difficulty separating disease-related F 
cells and fetal RBCs by the K-B acid-elution assay. For those 
D– postpartum women with increased F cells, FC assays us-
ing either anti-D or anti-HbF offer a more precise method 
for determining the dose of RhIG (Fig. 3).92–95 Some, but 
not most, hospitals managing deliveries and postpartum 
Rh immunoprophylaxis for women with sickle cell disease 
and other diagnoses known to be associated with increased 
numbers of F cells may have FC services readily available. 
The question arises, “What laboratory methods are avail-
able to ensure an adequate dose of RhIG for those women 
with an increased percentage of F cells?” An estimated 0.3 
to 1.0 percent of all obstetrical deliveries result in an FMH 
greater than 30 mL and require more than one vial of RhIG 
for adequate Rh immunoprophylaxis.4,20,96 However, the 
likelihood that a D– mother receiving only one vial of RhIG 
will become alloimmunized to D and form anti-D is only 0.07 
percent of all D– women who receive RhIG.97 Thus, despite 
technical limitations, the risk of failure of Rh immunopro-
phylaxis (alloimmunization) is very low. Nevertheless, the 
possibility of an FMH in a woman with increased F cells 
requiring additional doses of RhIG should be addressed. 
Recognizing that an inadequate dose of RhIG is likely to be 
completely adsorbed by D+ fetal RBCs in the maternal cir-
culation, Bowman97 notes that after administration of an 
adequate dose of RhIG, passive anti-D should be present in 
the maternal circulation. Following this rationale, some phy-
sicians advocate measuring anti-D titers after administration 
of RhIG to assess the need for additional doses of RhIG.98,99 
Mollison and colleagues100 consider this practice “unsound in 
principle,” as even when the D antigen concentration is low, 
not all anti-D is bound to RBCs. This opinion is maintained 
by Klein and Anstee,101 who revised and edited the most re-
cent edition of Mollison’s textbook. Ness and Salamon102 
studied anti-D titers in 30 recipients of RhIG and found no 
correlation between the titers and the volume calculated 
for FMHs. Measuring anti-D after an intramuscular dose of 
RhIG is an unreliable indicator of the adequacy of the dose 
of RhIG, and the practice is discouraged.4 The most specific 
assay for determining the adequacy of the dose of RhIG in a 
D– postpartum mother is one that reflects clearance of fetal 
D+ RBCs from the mother’s circulation. Mollison and col-
leagues100 recommend testing for clearance of D+ fetal RBCs 
using the rosette screen. Because the rosette screen is specific 
for D and is sufficiently sensitive to detect an FMH of 10 mL, 
we recommend this method for determining adequacy of the 
dose of RhIG when FC (anti-D or anti-HbF) is not available.
 In summary, FC for quantifying 
FMHs and determining the dose 
of RhIG remains an underutilized 
technology in hospitals in the Unit-
ed States. During the four decades 
since Herzenberg and others103 ad-
vocated using fluorescent-activated 
cell-sorting technology for laboratory 
diagnosis, our colleagues in hemato-
pathology have used FC to improve 
the precision of diagnoses for a wide 
range of hematologic diagnoses. A 
recent editorial in the American 
Journal of Clinical Pathology, “Be-
yond Gating: Capturing the Power 
of Flow Cytometry,” illustrates how 
effectively other disciplines have 
captured the promise of this tech-
nology.104 The present review reveals 
that those of us who are concerned 
with the laboratory basis of Rh im-
munoprophylaxis have not yet taken 
full advantage of the opportunities 
that FC offers. Analyzers with flow 
capabilities, reagent antibodies, and 
control reagents for FC are be-
coming increasingly available in 
the United States, making round-
the-clock service more accessible 
(Fig. 5). We encourage industry to 
develop and market FDA-cleared 
Fig. 5. Screen shot of a hematology analyzer (Cell-Dyne Sapphire, Abbott Laboratories, Ab-
bott Park, IL) illustrating the application of FC using monoclonal anti-HbF (QuikQuant, Trillium 
Diagnostics) to quantify a simulated FMH of 1.75 percent cord RBCs in adult RBCs (Fetaltrol, 
Trillium Diagnostics). The FL1 axis is the anti-HbF fluorescence signal, and the cord RBCs are 
highlighted by circles. Adult RBCs with lower fluorescence are clearly separated from cord 
RBCs with higher fluorescence. This example illustrates how a basic hematology analyzer can be 
adapted to quantify FMHs in a hospital clinical laboratory.
Rh immunoprophylaxis
IMMUNOHEMATOLOGY, Volume 26, Number 3, 2010100
reagents for FC applications for quantifying fetal RBCs 
for Rh immunoprophylaxis. We encourage directors of 
hospital and reference laboratories to look positively to the 
opportunities of FC for quantifying FMHs.
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